Showing results (261-270 of 716) with videos related to

Sort By:
Pageof 72
Cancer|July 7, 2007
Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantationDimitrios P Kontoyiannis, Georgios Chamilos, Russell E Lewis, et al.
Blood|June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsMin Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.
Leukemia & Lymphoma|March 4, 2010
Late relapses in acute myeloid leukemia: analysis of characteristics and outcomeDushyant Verma, Hagop Kantarjian, Stefan Faderl, et al.
Leukemia Research|May 10, 2006
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cellsSrdan Verstovsek, Francis J Giles, Alfonso Quintás-Cardama, et al.
Haematologica|April 26, 2012
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemiaAziz Nazha, Jorge Cortes, Stefan Faderl, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
The Lancet. Haematology|March 15, 2017
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trialLucia Masarova, Keyur P Patel, Kate J Newberry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutationSrdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, et al.
British Journal of Haematology|November 18, 2003
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemiaDeborah A Thomas, Elihu Estey, Francis J Giles, et al.
Cancer|January 26, 2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeHagop Kantarjian, Miloslav Beran, Jorge Cortes, et al.
Pageof 72